Glenmark Pharmaceuticals has been granted a patent for hetero-dimeric immunoglobulins that target both the human CD3 antigen and the human CD38 antigen. The patent also covers antibodies and derivatives that bind to the human CD38 antigen for therapeutic or diagnostic use. GlobalData’s report on Glenmark Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Glenmark Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. Glenmark Pharmaceuticals's grant share as of September 2023 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Bispecific antibody binding to human cd38 antigen
A recently granted patent (Publication Number: US11773166B2) discloses a bispecific antibody or fragment thereof that binds to human CD38. The antibody consists of specific amino acid sequences in its heavy chain variable region (CDR1, CDR2, and CDR3) and light chain variable region (CDR1, CDR2, and CDR3). The patent claims that the bispecific antibody can be a murine antibody, chimeric antibody, or a humanized antibody.
The patent also describes that the bispecific antibody can have different heavy chain variable region sequences and/or light chain variable region sequences, as long as they are at least 80% identical to the non-CDR region of the specified sequences. Additionally, the bispecific antibody can contain human heavy and/or light chain constant regions, specifically IGHG1, non-fucosylated IGHG1, and IGHG4.
The patent further mentions that the bispecific antibody can be in various forms, including Fab, Fab', Fab'-SH, Fd, Fv, dAb, F(ab')2, scFv, bispecific single chain Fv dimers, diabodies, triabodies, and scFv. It can also include an anti-CD3 antibody fragment with specific amino acid sequences in its heavy chain variable region (CDR1, CDR2, and CDR3) and light chain variable region (CDR1, CDR2, and CDR3).
The patent claims that the bispecific antibody or fragment thereof, along with a pharmaceutically acceptable carrier, can be used in a composition. Additionally, the bispecific antibody or fragment thereof can be linked to a therapeutic agent to form an immunoconjugate.
The patent also discloses a method of treating various malignant hematological diseases, including multiple myeloma, B-cell chronic lymphocytic leukemia, B-cell acute lymphocytic leukemia, and others. The method involves administering the bispecific antibody or fragment thereof to a subject in need of treatment.
In summary, the granted patent describes a bispecific antibody or fragment thereof that specifically binds to human CD38. The antibody can have different sequences in its heavy and light chain variable regions, and it can be in various forms. The patent also covers the use of the bispecific antibody in compositions and immunoconjugates, as well as its application in treating malignant hematological diseases.
To know more about GlobalData’s detailed insights on Glenmark Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
